IL6 and COVID-19: We did not find a significant difference between the 2 groups of patients regarding systemic inflammatory markers (CRP, ferritin, IL-6 levels), as found in 2 large cohorts of 575 and 697 patients with COVID-19 and pulmonary thrombosis.[26,27] Regarding age, sex, and comorbidities, our results were similar to those of the aforementioned studies, with no difference between the 2 groups.